Elicio Therapeutics, Inc. (ELTX)
| Market Cap | 242.46M +175.8% |
| Revenue (ttm) | n/a |
| Net Income | -40.19M |
| EPS | -2.42 |
| Shares Out | 18.40M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 114,874 |
| Open | 13.93 |
| Previous Close | 13.93 |
| Day's Range | 13.01 - 14.60 |
| 52-Week Range | 7.37 - 14.97 |
| Beta | 1.44 |
| Analysts | Buy |
| Price Target | 18.00 (+36.57%) |
| Earnings Date | May 11, 2026 |
About ELTX
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph node-targeted AMP peptide treatment for mutant b-raf murine sarcoma viral oncogene homolog B1-(BRAF) driven cancers, and ELI-008, a multivalent lymph node-targe... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for ELTX stock is "Buy." The 12-month stock price target is $18.0, which is an increase of 36.57% from the latest price.
News
Elicio Therapeutics publishes data on AMP-DNA adjuvant technology
Elicio Therapeutics (ELTX) announced the publication of a peer-reviewed manuscript in Science Advances describing a series of novel AMP-DNA adjuvant candidates built from the lymph node-targeting Amph...
Elicio Therapeutics Announces Publication in Peer-Reviewed Journal Science Advances Highlighting Potent and Durable Immune Responses Driven by Company's AMP-DNA Adjuvant Technology
BOSTON, June 01, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for...
Elicio Therapeutics Transcript: Bank of America Global Healthcare Conference 2026
The AMP platform is advancing immunotherapeutics targeting KRAS and other mutations, with ELI-002 showing robust immune responses and improved survival in early trials. Phase II results in adjuvant pancreatic cancer are expected mid-2026, with strong financial support for ongoing development.
Elicio Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Updates
In the ongoing Phase 2 AMPLIFY-7P study evaluating ELI-002 7P in patients with pancreatic ductal adenocarcinoma (“PDAC”), the event-driven primary disease-free survival (“DFS”) analysis is anticipated...
Elicio Therapeutics Earnings release: Q1 2026
Elicio Therapeutics released its Q1 2026 earnings on May 11, 2026, summarizing the period's financial results.
Elicio Therapeutics Quarterly report: Q1 2026
Elicio Therapeutics has published its Q1 2026 quarterly earnings report on May 11, 2026.
Elicio Therapeutics to Present at the Bank of America Healthcare Conference
BOSTON, April 30, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies fo...
Elicio Therapeutics Reports Inducement Grants
BOSTON, April 16, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies fo...
Elicio Therapeutics initiated with a Buy at Ladenburg
Ladenburg initiated coverage of Elicio Therapeutics (ELTX) with a Buy rating and $20 price target The firm says the company is creating the new standard of care in minimal residual…
Elicio Therapeutics price target raised to $17 from $13 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Elicio Therapeutics (ELTX) to $17 from $13 and keeps a Buy rating on the shares. To reflect the data seen to date,…
Elicio Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Updates
BOSTON, March 12, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies fo...
Elicio Therapeutics Registration statement: Registration Filing
Elicio Therapeutics filed a registration statement on March 12, 2026, providing details about a securities offering with the SEC.
Elicio Therapeutics Earnings release: Q4 2025
Elicio Therapeutics released its Q4 2025 earnings on March 12, 2026, summarizing the period's financial results.
Elicio Therapeutics Annual report: Q4 2025
Elicio Therapeutics has published its Q4 2025 annual report on March 12, 2026.
Elicio Therapeutics initiated with a Buy at Rodman & Renshaw
Rodman & Renshaw analyst Michael King initiated coverage of Elicio Therapeutics (ELTX) with a Buy rating and $17 price target ELI-002 represents “a paradigm shift in mKRAS immunotherapy,” says the…
Elicio Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference
The company presented updates on its AMP platform for lymph node-targeted immunotherapies, highlighting strong clinical results for ELI-002 in KRAS-mutant cancers, robust T cell responses, and a favorable safety profile. Phase II results are expected in H1 2026, with plans for pipeline expansion and a Phase III trial.
Elicio Therapeutics Registration statement: Registration Filing
Elicio Therapeutics filed a registration statement on March 2, 2026, providing details about a securities offering with the SEC.
Elicio Therapeutics files $400M mixed securities shelf
16:25 EST Elicio Therapeutics (ELTX) files $400M mixed securities shelf
Elicio Therapeutics Registration statement: Registration Filing
Elicio Therapeutics filed a registration statement on February 27, 2026, providing details about a securities offering with the SEC.
Elicio Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference
BOSTON, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for...
Elicio Therapeutics’ ELI-002 7P shows antigen spreading in Phase 2 trial
Elicio Therapeutics (ELTX) announced that analysis of a subset of patients in the ongoing Phase 2 AMPLIFY-7P trial has demonstrated that a majority of evaluated patients – 13 out of…
Elicio Therapeutics Reports Antigen Spreading to Patient-Specific Neoantigens Beyond mKRAS in Ongoing Phase 2 AMPLIFY-7P Trial
Antigen spreading was evaluated in a subset of Phase 2 patients to assess the ability of ELI-002 7P to broaden immune responses to personalized tumor neoantigens not present in the targeted immunother...
Elicio Therapeutics appoints Marc Wolfgang as CTO
Elicio Therapeutics (ELTX) announced the appointment of Marc Wolfgang, M.S. as Chief Technology Officer. He most recently served as Senior Vice President of Technical Development and Operations at Sai...
Elicio Therapeutics Appoints Veteran CMC and Technical Operations Executive Marc J. Wolfgang as Chief Technology Officer
BOSTON, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for...
Elicio Therapeutics files to sell 103,225 shares of common stock for holders
17:05 EST Elicio Therapeutics (ELTX) files to sell 103,225 shares of common stock for holders